Tifcemalimab Clinical Trials Development Insight Delhi, April 27, 2023 (GLOBE NEWSWIRE) -- Tifcemalimab also known as TAB004 and JS004 is the world’s first in human recombinant humanized anti- BTLA (B and T lymphocyte attenuator) monoclonal...